SG10202107832UA - Dosage regimen for treatment of solid tumors - Google Patents
Dosage regimen for treatment of solid tumorsInfo
- Publication number
- SG10202107832UA SG10202107832UA SG10202107832UA SG10202107832UA SG10202107832UA SG 10202107832U A SG10202107832U A SG 10202107832UA SG 10202107832U A SG10202107832U A SG 10202107832UA SG 10202107832U A SG10202107832U A SG 10202107832UA SG 10202107832U A SG10202107832U A SG 10202107832UA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- solid tumors
- dosage regimen
- regimen
- dosage
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662381911P | 2016-08-31 | 2016-08-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202107832UA true SG10202107832UA (en) | 2021-09-29 |
Family
ID=59772787
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202107832UA SG10202107832UA (en) | 2016-08-31 | 2017-08-24 | Dosage regimen for treatment of solid tumors |
| SG11201901325UA SG11201901325UA (en) | 2016-08-31 | 2017-08-24 | Dosage regimen for treatment of solid tumors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901325UA SG11201901325UA (en) | 2016-08-31 | 2017-08-24 | Dosage regimen for treatment of solid tumors |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20190209581A1 (en) |
| EP (1) | EP3506905B1 (en) |
| JP (2) | JP2019526632A (en) |
| KR (1) | KR102512899B1 (en) |
| CN (2) | CN109562114A (en) |
| AU (1) | AU2017321011B2 (en) |
| BR (1) | BR112019002461A2 (en) |
| CA (1) | CA3035616A1 (en) |
| IL (2) | IL305136A (en) |
| MA (1) | MA46086A (en) |
| MX (1) | MX2019002066A (en) |
| SG (2) | SG10202107832UA (en) |
| WO (1) | WO2018044662A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI609687B (en) | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | Targeted treatment of leiomyosarcoma |
| EP3442529B1 (en) | 2016-04-12 | 2021-05-26 | Eli Lilly and Company | Combination therapy with notch and cdk4/6 inhibitors for the treatment of lung cancer |
| KR102418766B1 (en) | 2016-04-12 | 2022-07-08 | 일라이 릴리 앤드 캄파니 | Combination Therapy of Notch and a PI3K/mTOR Inhibitor for Use in the Treatment of Cancer |
| ES2904880T3 (en) | 2016-05-20 | 2022-04-06 | Lilly Co Eli | Combination therapy with Notch and PD-1 or PD-L1 inhibitors |
| CA3039405A1 (en) | 2016-10-12 | 2018-04-19 | Eli Lilly And Company | Targeted treatment of mature t-cell lymphoma |
| CN117357638A (en) | 2017-02-17 | 2024-01-09 | 弗雷德哈钦森癌症中心 | Combination therapy for the treatment of BCMA-related cancers and autoimmune disorders |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US46206A (en) | 1865-02-07 | Improved vessel for holding petroleum | ||
| WO2008112249A1 (en) * | 2007-03-13 | 2008-09-18 | Trustees Of Columbia University In The City Of New York | Synergistic interaction of notch-1 inhibitors with glucocorticoids |
| ES2781949T3 (en) * | 2007-11-13 | 2020-09-09 | Meritage Pharma Inc | Compositions for the treatment of gastrointestinal inflammation |
| AR087107A1 (en) * | 2011-07-27 | 2014-02-12 | Lilly Co Eli | INHIBITOR COMPOUND OF THE SIGNALING OF THE NOTCH TRAJECTORY |
| KR20170029490A (en) * | 2014-07-11 | 2017-03-15 | 제넨테크, 인크. | Notch pathway inhibition |
| TWI609687B (en) * | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | Targeted treatment of leiomyosarcoma |
-
2017
- 2017-08-24 KR KR1020197005847A patent/KR102512899B1/en active IP Right Grant
- 2017-08-24 IL IL305136A patent/IL305136A/en unknown
- 2017-08-24 US US16/328,267 patent/US20190209581A1/en active Pending
- 2017-08-24 MA MA046086A patent/MA46086A/en unknown
- 2017-08-24 AU AU2017321011A patent/AU2017321011B2/en active Active
- 2017-08-24 EP EP17761723.0A patent/EP3506905B1/en active Active
- 2017-08-24 WO PCT/US2017/048308 patent/WO2018044662A1/en unknown
- 2017-08-24 IL IL264924A patent/IL264924B2/en unknown
- 2017-08-24 CN CN201780052146.2A patent/CN109562114A/en active Pending
- 2017-08-24 MX MX2019002066A patent/MX2019002066A/en unknown
- 2017-08-24 BR BR112019002461A patent/BR112019002461A2/en unknown
- 2017-08-24 SG SG10202107832UA patent/SG10202107832UA/en unknown
- 2017-08-24 CN CN202310314953.4A patent/CN116473978A/en active Pending
- 2017-08-24 CA CA3035616A patent/CA3035616A1/en active Pending
- 2017-08-24 SG SG11201901325UA patent/SG11201901325UA/en unknown
- 2017-08-24 JP JP2019531873A patent/JP2019526632A/en active Pending
-
2022
- 2022-12-27 JP JP2022209634A patent/JP2023052108A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2019002066A (en) | 2019-06-03 |
| US20190209581A1 (en) | 2019-07-11 |
| JP2023052108A (en) | 2023-04-11 |
| KR20190042591A (en) | 2019-04-24 |
| CN109562114A (en) | 2019-04-02 |
| JP2019526632A (en) | 2019-09-19 |
| IL264924A (en) | 2019-04-30 |
| CN116473978A (en) | 2023-07-25 |
| WO2018044662A1 (en) | 2018-03-08 |
| IL264924B2 (en) | 2024-01-01 |
| SG11201901325UA (en) | 2019-03-28 |
| IL264924B1 (en) | 2023-09-01 |
| AU2017321011B2 (en) | 2023-08-03 |
| BR112019002461A2 (en) | 2019-05-14 |
| AU2017321011A1 (en) | 2019-02-21 |
| CA3035616A1 (en) | 2018-03-08 |
| MA46086A (en) | 2019-07-10 |
| EP3506905B1 (en) | 2024-03-20 |
| IL305136A (en) | 2023-10-01 |
| EP3506905A1 (en) | 2019-07-10 |
| KR102512899B1 (en) | 2023-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1247202A1 (en) | Compounds for the treatment of cancer | |
| HK1258779A1 (en) | Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer | |
| HK1247129A1 (en) | Combination therapy for the treatment of cancer | |
| FI3936130T3 (en) | Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders | |
| HK1251475A1 (en) | Combination therapy for the treatment of cancer | |
| ZA201806819B (en) | Pharmaceutical combinations for the treatment of cancer | |
| IL259996A (en) | Combinations for the treatment of cancer | |
| HK1254882A1 (en) | Combination therapies for treatment of cancer | |
| IL285077A (en) | Compounds for treatment of cancer | |
| SG10202107832UA (en) | Dosage regimen for treatment of solid tumors | |
| ZA201900052B (en) | Pharmaceutical combinations for treating cancer | |
| IL259101A (en) | Melflufen dosage regimens for cancer | |
| HK1253098A1 (en) | Dosage regimen of mdm2 inhibitor for treating cancers | |
| IL265762A (en) | Dosing regimen of avelumab for the treatment of cancer | |
| ZA201704589B (en) | Compounds for the treatment of cancer | |
| GB201614179D0 (en) | Dosage regimen for the treatment of endometriosis | |
| IL236381A0 (en) | Pharmaceutical compositions for treatment of cancer |